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The prevalence and impact of imaging findings detected during screening procedures in patients 
undergoing transcranial MR‑guided Focused Ultrasound (tcMRgFUS) thalamotomy for functional 
neurological disorders has not been assessed yet. This study included 90 patients who fully completed 
clinical and neuroradiological screenings for tcMRgFUS in a single‑center. The presence and location 
of preoperative imaging findings that could impact the treatment were recorded and classified 
in three different groups according to their relevance for the eligibility and treatment planning. 
Furthermore, tcMRgFUS treatments were reviewed to evaluate the number of transducer elements 
turned off after marking as no pass regions the depicted imaging finding. A total of 146 preoperative 
imaging findings in 79 (87.8%) patients were detected in the screening population, with a significant 
correlation with patients’ age (rho = 483, p < 0.001). With regard of the group classification, 119 
(81.5%), 26 (17.8%) were classified as group 1 or 2, respectively. One patient had group 3 finding and 
was considered ineligible. No complications related to the preoperative imaging findings occurred in 
treated patients. Preoperative neuroradiological findings are frequent in candidates to tcMRgFUS and 
their identification may require the placement of additional no‑pass regions to prevent harmful non‑
targeted heating.
Transcranial Magnetic Resonance imaging-guided Focused Ultrasound (tcMRgFUS) is a novel incisionless ste-
reotactic procedure based on the thermal ablation of a brain target using a high-intensity focused ultrasound 
(HI-FU) beam guided by MR anatomical imaging and thermal  maps1. The clinical applications of tcMRgFUS 
are rapidly expanding and the procedure is nowadays indicated for the treatment of medication-refractory 
essential tremor, idiopathic unilateral tremor-dominant Parkinson’s disease, and neuropathic  pain2. Randomized 
controlled trials and multiple studies have demonstrated the clinical benefits of tcMRgFUS for the treatment of 
movement disorders, with significant improvement in tremor scales and quality of  life3–9. Moreover, experimental 
studies have explored the potential use of low intensity focused ultrasound (LI-FU) tcMRgFUS for transient 
blood brain-barrier opening in intracranial  tumors10–13 and neurodegenerative  disorders14–17. Considering move-
ment disorders treatments, tcMRgFUS has demonstrated similar clinical efficacy and higher safety compared to 
other stereotactic procedures such as deep brain stimulation, radiofrequency ablation, or stereotactic radiosur-
gery due to the lack of ionizing radiations, craniotomy, or hardware-related  complications18–22.
Rapid expansion in clinical applications poses a question regarding the clinical relevance of neurological con-
ditions and neuroradiological imaging findings detected during screening procedures. Indeed, all candidates to 
tcMRgFUS procedures must undergo CT and MRI for treatment planning and simulation. During a tcMRgFUS 
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procedure, the HI-FU waves emanating from the helmet-like transducer must travel through multiple tissue lay-
ers on a large head area prior to reaching the desired thalamic target. The acoustic properties and the thickness of 
each single tissue layer will influence the amount of energy carried by the acoustic wave that will be transmitted 
rather than reflected or absorbed. The energy absorption may result in unwanted thermal exposures. Thus, is 
mandatory to identify energy absorbing or sensitive structures on neuroradiological examinations to block the 
passage of the HI-FU beams through.
Nowadays only general contraindications to tcMRgFUS procedures are reported in the “Information for 
Prescribers” available from the  vendor23. However, candidates to tcMRgFUS may present incidental findings 
on screening imaging studies that may influence the passage of the ultrasound beam or significantly impact the 
number of active transducer elements for the procedure. Prior studies have reported how common incidental 
brain findings on MRI are in the general  population24–27. Once excluded any potentially clinically relevant inci-
dental finding requiring urgent or immediate referral, which in fact would represent an absolute contraindica-
tion to the treatment, there are no precise indications about other incidental neuroradiological findings. To our 
knowledge, no prior study has assessed the implications of incidental neuroradiological findings and the role of 
preoperative imaging in tcMRgFUS treatment.
Therefore, the purpose of this study was to assess the prevalence and significance of imaging findings detected 
during screening procedures in candidates to tcMRgFUS thalamotomy and to determine their impact for the 
tcMRgFUS treatment eligibility.
Materials and methods
The institutional review board (“Comitato Etico Palermo 1”) approved this study. All subjects provided written 
informed consent before enrolling for tcMRgFUS in accordance with the Declaration of Helsinki. This study is 
a retrospective analysis of prospectively-enrolled cohort undergoing clinical and neuroradiological screening 
for tcMRgFUS.
Population. The study population included all consecutive adult patients prospectively enrolled for tcMRg-
FUS screening procedures between January 2015 and December 2019. A total of 298 patients underwent clinical 
screening as potential candidates for tcMRgFUS. In our University Hospital all the potential candidates were 
clinically evaluated by neurologists (specialized in movement disorders) and neurosurgeons (with expertise in 
conventional functional neurosurgery techniques) in order to confirm the clinical indication for the treatment. 
Clinical approved (CE marking of conformity no 2110597CE01) indications for treatment were medical-refrac-
tory essential tremor, idiopathic asymmetrical tremor-dominant Parkinson’s disease, and neuropathic pain. A 
few patients with different clinical conditions have been evaluated for experimental applications too (multiple 
sclerosis-associated tremor, dystonia, and vascular tremor). The Clinical Rating Scale for Tremor and the Essen-
tial Tremor Rating Assessment Scale were used for the clinical assessment of essential tremor patients and the 
Unified Parkinson’s Disease Rating for Parkinson disease  patients28–30. At our center patients without clinical 
indication or with lack of definitive diagnosis were excluded and did not undergo screening imaging examina-
tions. Patients considered suitable for tcMRgFUS underwent preoperative CT and MRI the same week of the 
clinical evaluations. CT was acquired in order to calculate the skull-density ratio (SDR). This score quantifies 
the discrepancy in Hounsfield Units between the spongious and cortical bone and it is mandatory to apply the 
phase correction algorithm for the HI-FU beams that allow a precise trans-cranial focusing and energy release 
on  target31,32. CT is also used to identity frontal sinuses and calcifications that may interfere the HI-FU trans-
mission. MRI was performed in order to plan the tcMRgFUS treatment simulation, to detect any preoperative 
imaging findings that may affect the procedure, and to delineate the optimal target  coordinates2. Only patients 
that completed the clinical and neuroradiological screening were included for the present study.
MRI technique. Patients that passed clinical screening underwent MRI screening using a 1.5 T MR scan-
ner (Signa HDxt; GE Medical Systems). In our center the standard screening protocol included the following 
sequences: 2D fast recovery fast spin echo (FRFSE) T2-weighed (T2w) images (basal ganglia region coverage) 
acquired on sagittal, coronal and axial planes, and axial T2w fast spin echo-inversion recovery (FSE-IR) for 
white matter according to the anterior commissure—posterior commissure (AC-PC) anatomical landmarks; 
axial T1-weighed (T1w) 3D prepped inversion recovery fast spoiled gradient echo (brain volume acquisition, 
BRAVO); sagittal T2w 3D fluid-attenuated inversion-recovery with fat saturation (3D FLAIR fat sat); 3D suscep-
tibility-weighted angiography (SWAN), diffusion weighted images (DWI) with b values of 0 and 1000 s/mm2; 
and 3D BRAVO and axial T1 FSE acquired after the i.v. administration of 0.1 mml/kg of gadobutrol (Gadovist, 
Bayer HealthCare) using an automatic injector (Medrad Spectris Solaris EP, Bayer Healtcare). MRI acquisition 
parameters are detailed on Table 1. The same protocol was repeated at 48-h, 6-months, and subsequent follow-
ups (1, 2 and 5-years).
CT technique. Screening CT imaging were acquired using a multidetector 16-channel CT scanner (Bright-
Speed, GE Medical Systems). The protocol was as follow: sequential acquisition with no gantry inclination; tube 
voltage 120 kV; tube current 220 mAs; slice thickness 1.25 mm; spacing 0 mm; reconstruction kernel bone plus. 
The SDR was calculated using the ExAblate workstation (INSIGHTEC Ltd.).
Procedure details. At our site tcMRgFUS thalamotomies were performed using a focused ultrasound 
(FUS) equipment (ExAblate 4000; INSIGHTEC Ltd.) integrated with the same MR unit used for screenings. The 
FUS equipment is composed by a 30 cm wide hemispheric 1024-elements phased-array transducer operating at 
650 kHz. All the procedures were performed by a single primary operator who had the full control of the work-
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station, in collaboration with a dedicated trans-disciplinary team (including neuroradiologists, neurologists, 
neurosurgeons, and medical physicists).
Detailed description of tcMRgFUS thalamotomy have been extensively described in prior  reports2,31,33. Impor-
tantly, to avoid the passage of the HI-FU beams through sensitive structures and thus harmful non-targeted 
heating, no-pass regions (NPRs) must be marked on coregistered screening CT and MRI examinations. Typical 
NPRs were placed during treatment planning on CT images outlining frontal sinuses, choroid plexus and intrac-
ranial  calcifications2,31. On treatment day, additional NPRs were marked if needed (folds of the silicon membrane 
as well as nevi, skin scars, or other skin defect revealed after patient’s head was shaven that may interfere with 
HI-FU beams). More NPRs were placed according to the evidence of preoperative findings on screening CT and 
MRI, considering the risk of ultrasound absorption and related unwanted heating. In our practice we calculated 
the maximum diameter of each incidental imaging finding on the MRI sequence in which it was best depicted. 
A volumetric NPR was then placed with the treatment workstation (ExAblate, INSIGHTEC Ltd.) eventually 
using MRI volume coordinates if the depicted imaging finding was not appreciable on planning T2-w FRFSE 
images. The NPRs prevent unwanted exposures by turning off all the transducer elements whose beam would 
pass through it. Notably, at least 700 elements should be active to allow the  treatment2,31.
Imaging analysis. Preoperative CT and MRI studies were retrospectively evaluated by two radiologists 
(C.G. with 15 and R.C. with 5 years of experience, respectively). Imaging studies were reviewed using an inde-
pendent workstation equipped with Horos (a free and open source code software program that is distributed free 
of charge under the LGPL license at Horosproject.org). Preoperative incidental imaging findings were defined 
as any lesion, mass, or potentially relevant abnormality for the tcMRgFUS procedure detected on CT and MRI 
screening examinations. Findings as anatomical variants of the sinus cavities, or intracranial calcifications were 
not included as these structures are routinely marked with NPRs in all patients during treatment planning. The 
presence and location of imaging findings on CT and MRI in each patient was registered as well as the MRI 
sequences where the findings could be better identified and characterized. For SWAN sequences only the pres-
ence of hypointense lesions non-compatible with calcifications on corresponding CT images were recorded.
All patients treated with tcMRgFUS were reviewed using the dedicated workstation (ExAblate, INSIGHTEC 
Ltd.) in order to evaluate the additional number of transducers that were shut off to prevent HI-FU transmission 
due to the presence of above findings marked as NPRs. For the shut off transducers, it was only considered the 
number of elements due to the specific preoperative findings detected. This latter is related to the NPRs vol-
ume and location. Notably, even if the NPRs were placed below the plan passing through the treatment target, 
they were recorded because these may result in elements being shut off if crossed by far field HI-FU  beams31. 
Additional treatment parameters such as SDR, skull area exposed to the HI-FU beams, and number of active 
transducers elements were registered in treated patients.
Based on the review of all tcMRgFUS procedures and trans-disciplinary discussion, preoperative findings 
were classified in three different groups according to their relevance (in terms of energy absorbing structures or 
sensitive tissues) for the eligibility and treatment planning:
• Group 1: not significant or scarcely significant, if they should not influence the treatment planning or require 
any NPRs.
• Group 2: potentially significant, including findings that may impede HI-FU transmission and require place-
ment of NPRs on the planning software, through which no acoustic energy should be delivered, or may 
represent potential treatment contraindications.
• Group 3: significant, if they represent a clinically relevant incidental finding requiring urgent or immediate 
referral thus an absolute contraindication for the treatment.
Table 1.  MRI acquisition parameters used for screening and follow-up studies with 1.5 T MRI scanner. TR 
repetition time, TE echo time, TI inversion time, NEX number of excitations, FOV field of view, FRFSE fast 
recovery fast spin echo, FSE fast spin echo, IR inversion recovery, BRAVO brain volume acquisition, FLAIR 
Fat Sat fluid-attenuated inversion-recovery with fat signal saturation, EP echo planar, DWI diffusion weighed 
imaging, SWAN susceptibility-weighted angiography. a Basal ganglia coverage.
Sequences Slice thickness (mm) Gap TR (ms) TE (ms) IT (ms) Matrix NEX FOV (cm)
Sagittal T2w  FRFSEa 2 0 5269 97 n.a 224 × 224 5 24 × 24
Coronal T2w  FRFSEa 2 0 4387 108 n.a 320 × 288 5 24 × 24
Axial T2w  FEFSEa 2 0 4380 108 n.a 320 × 288 5 24 × 24
Axial T2w FSE-IRa 2 0 4500 40 300 320 × 288 1 24 × 24
Axial T1w 3D IR BRAVO 1 0 12.4 5.2 450 256 × 256 1 25.6 × 25.6
Sagittal T2w 3D FLAIR Fat Sat 1.2 0 6000 124.6 1866 224 × 224 1 26 × 26
EP-DWI 5 1 7000 Shortest n.a 128 × 128 1 24 × 24
Axial 3D SWAN 3 0 78.5 50 n.a 288 × 224 1 23 × 23
Axial T1w FSE 5 1 475 Shortest n.a 256 × 192 2 24 × 24
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Statistical analysis. Continuous variables were expressed as mean and standard deviation (SD) while cat-
egorical variables as numbers and percentages. The Mann–Whitney U test was performed to assess the differ-
ence of the number of preoperative findings in patients < 65 years compared to patients ≥ 65 years (cutoff based 
on the mean age of the included patients) and the difference in number of treatment elements in patients with 
or without group 2 findings. Correlation between the number of preoperative findings and patients’ age was 
calculated using the Spearman’s rank correlation coefficient (Spearman’s rho).
Statistical significance level was set at p < 0.05. Statistical analysis was conducted by using SPSS software 
(Version 25.0. Armonk, NY, USA: IBM Corp).
Ethical approval. All procedures performed in the studies involving human participants were in accord-
ance with the ethical standards of the institutional and/or national research committee and with the 1964 Hel-
sinki Declaration and its later amendments or comparable ethical standards.
Informed consent. Informed consent was obtained from all individual participants included in the study.
Results
Population. Ninety patients (67 men and 23 women, mean age at the time of screening: 64.7 ± 12.1 years, 
range 23–86  years) underwent preoperative CT and MRI before tcMRgFUS (Table  2). Indications for treat-
ment were either essential tremor (n = 70, 77.8%), idiopathic asymmetrical tremor-dominant Parkinson’s disease 
(n = 15, 16.7%), multiple sclerosis (n = 3, 3.3%; two of which with essential tremor comorbidity), or neuropathic 
pain (n = 2, 2.2%). After multidisciplinary evaluation, additional 14 patients were considered not eligible for the 
treatment due to clinical indications (i.e. not definitive diagnosis of movement disorder or too subtle symptoms, 
n = 6) or MRI findings (n = 1) (Fig. 1). In addition, seven patients refused to be treated after completing the 
screening tests and being extensively informed of benefits and potential risks of the treatment. Therefore, 76 
patients were finally considered eligible and provided full consent for the tcMRgFUS procedure. Treatment was 
completed successfully placing a lesion in the targeted area in 69 (90.7%) patients (54 men and 15 women, mean 
age 65.5 ± 11.5 years, range 26–86 years). Five (6.6%) procedures were aborted before realizing any sonication 
or placing any permanent lesion (due to acute onset of laryngospasm, unbearable headache, decompensated 
hypertension, nausea and vomiting, panic attack, respectively) and two (2.7%) procedures failed because it was 
not possible to achieve therapeutic thermal rise (above 50° during high-energy sonications) due to unfavorable 
skull characteristics (SDR of 0.35 and 0.38, respectively). Parameters of the treated patients were (mean ± SD): 
SDR, 0.50 ± 0.09; number of elements, 930.4 ± 47.9; skull area, 344.5 ± 27.2.
Prevalence of preoperative findings. A total of 146 preoperative imaging findings were detected in the 
screening population (Table 3). Preoperative findings were present in 79 (87.8%) patients, while 11 (12.2%) did 
not have any incidental imaging finding. Overall, 33 (36.7%) patients had a single finding, 29 (32.2%) had two 
findings, 13 (14.5%) had 3 findings, and 4 (4.4%) had 4 findings. There was a statistically significant positive cor-
relation between the number of preoperative findings in each patient and the patients’ age (rho = 483, p < 0.001) 
(Fig. 2), particularly patients older than 65 years had significantly higher number of preoperative findings com-
pared to patients < 65 years (1.8 ± 1.0 vs 1.1 ± 0.8; p = 0.001).
Gliotic foci were the most common neuroradiological finding (n = 57, 39.0% of all findings), with an over-
all prevalence of 63.3%. Other common preoperative findings were chronic hypoxic-ischemic encephalopathy 
(n = 27, 18.5%), SWAN hypointense lesions (n = 14, 9.5%), and aracnoidocele (n = 12, 8.2%).







Mean ± SD 64.7 ± 12.1
Range 23–86
Tremor etiology
Essential tremor 70 (77.8%)
Parkinson tremor 15 (16.7%)
Multiple sclerosis 3 (3.3%)
Neuropathic pain 2 (2.2%)
SDR
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Relevance of preoperative findings. No complications related to the reported preoperative imaging 
findings were registered in our population at intraoperative imaging or subsequent MRI follow-ups.
With regard of the group classification, 119 (81.5%) preoperative findings belonged to group 1 and they 
did not require any modification in the treatment planning. Twenty-six (17.8%) neuroimaging findings in 23 
(25.6%) patients were classified as group 2, since they may represent potential contraindications or may require 
the placement of NPRs during procedure planning, through which no acoustic energy should be delivered. 
SWAN hypointense lesions were the most common finding in the group 2 (Fig. 3), with a prevalence of 16.7%. 
Three (3.3%) patients had multiple sclerosis lesions (active plaque revealed at screening MRI in one case), 
of which the two with essential tremor comorbidity were successfully treated (without complications neither 
evidence of disease activity nor progression in the follow-up period) while one procedure was aborted (acute 
onset of laryngospasm before starting the treatment in the patient who had the active plaque at screening MRI). 
Figure 1.  Flow diagram of the screening and treatment population.
Table 3.  Number and prevalence of preoperative findings in candidates for tcMRgFUS.
Preoperative findings Number (%) Prevalence CT detected Group
Gliotic foci 57 (39.0%) 63.3% 0 (0%) 1
Chronic hypoxic-ischemic encephalopathy 27 (18.5%) 30.0% 0 (0%) 1
SWAN hypointense lesion 14 (9.5%) 15.5% 0 (0%) 2
Aracnoidocele 12 (8.2%) 13.3% 0 (0%) 1
Developmental venous anomaly 5 (3.4%) 5.5% 0 (0%) 1
Lacunar infarct 5 (3.4%) 5.5% 0 (0%) 1
Multiple sclerosis lesion (not active) 3 (2.0%) 3.3% 0 (0%) 2
Cavernoma 3 (2.0%) 3.3% 1 (33.3%) 2
Meningioma 2 (1.4%) 2.2% 1 (50.0%) 2
Cavum Vergae 2 (1.4%) 2.2% 2 (100%) 1
Subdural hygroma 2 (1.4%) 2.2% 0 (0%) 1
Pineal Cyst 2 (1.4%) 2.2% 0 (0%) 1
Bone or subcutaneous lesions 2 (1.4%) 1.1% 2 (100%) 2
Multiple sclerosis lesion (active) 1 (0.7%) 1.1% 0 (0%) 2
Subdural hematoma 1 (0.7%) 1.1% 1 (100%) 3
Metallic foreign body (sliver in the frontal subcutaneous tissue) 1 (0.7%) 1.1% 1 (100%) 2
Asymmetry of the lateral ventricles 1 (0.7%) 1.1% 1 (100%) 1
Basilar artery vascular ectasia 1 (0.7%) 1.1% 0 (0%) 1
Cavum septum pellucidum 1 (0.7%) 1.1% 1 (100%) 1
Choroidal fissure cysts 1 (0.7%) 1.1% 0 (0%) 1
Mega cisterna magna 1 (0.7%) 1.1% 0 (0%) 1
Acoustic schwannoma 1 (0.7%) 1.1% 0 (0%) 1
Temporal bone lesion (petrous apicitis) 1 (0.7%) 1.1% 1 (100%) 1
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Brain cavernomas were detected in three (3.3%) patients at preoperative MRI and they were located below the 
AC-PC plane in one patient (cerebellar hemisphere) and above in two patients. Two patients with a cavernoma 
located in the left cingulate cortex and in the left cerebellar hemisphere refused the treatment after being fully 
informed about the possible procedural risks. A 68-year-old man with a 5 mm hypointense SWAN lesion in the 
frontal lobe, very likely to be a small cavernoma, underwent tcMRgFUS without procedural complications. Two 
(2.2%) patients were discovered with lesions compatible with meningioma, including a 66-year-old woman with 
6 mm entirely calcified meningioma visible on CT imaging and with a dural base in the left temporal bone and 
an 81-year-old woman with an 11 mm meningioma with a dural base in the right frontal bone. Both patients 
were successfully treated without complications (Fig. 4). An unexpected millimetric metallic foreign body was 
detected in a 67-year-old man who performed CT screening after MRI. After collegial discussion, aware that the 
procedure could have been aborted in case of artifacts on MRI sequences used for monitoring the thermal rise 
during sonications, the patient was successfully treated with tcMRgFUS. A right subacute on chronic subdural 
hematoma was discovered in a 55-year-old man with history or chronic headache, and the patient was considered 
ineligible for the treatment (group 3); this patient would have been excluded anyway from treatment because of 
a way to low average SDR score (0.27).
Additional NPRs placed in patients with group 2 findings blocked a mean number of 4.6 (range 0–16) ele-
ments, accounting for a mean of 6.5% (range 0–24.2%) of all blocked elements during the treatment planning in 
patients undergoing tcMRgFUS procedure (Figs. 3 and 4). When considering routinely placed NPRs and elements 
blocked by preoperative imaging findings, there was no statistically significant difference in the final number 
of active elements in treated patients with or without group 2 findings (945.6 ± 34.9 vs 925.7 ± 50.6; p = 0.235).
MRI sequences for the characterization of preoperative findings. A retrospective analysis was 
conducted in order to evaluates the role of each MRI sequences in the detection of imaging findings according 
to the subgroup classification. T2w FRFSE and 3D-FLAIR characterized 118 (99.1%) and 116 (97.5%) group 
1 imaging findings, respectively. However, only 5 (19.2%) and 6 (23.1%) group 2 imaging findings could be 
characterized by using T2w FRFSE or 3D-FLAIR, respectively. Other group 2 imaging findings were observed 
with additional sequences, such as SWAN (n = 18, 69.2%, including 14 microbleeds, 3 cavernomas and 1 calci-
fied meningioma, the latter already appreciable on screening CT) and T1w post-contrast images (n = 3, 11.5%, 
including one cavernoma, one meningioma, and one active plaque in a multiple sclerosis patient). T1w post-
contrast images identified also one acoustic schwannoma and five developmental venous anomalies (one of 
which associated with a cerebellar cavernoma). Five group 2 imaging findings could be detected and character-
ized by CT, including one cavernoma, one calcified meningioma, two bone and subcutaneous lesions, and one 




Scientific Reports |         (2021) 11:2524  | https://doi.org/10.1038/s41598-021-82271-8
www.nature.com/scientificreports/
metallic foreign body. The subdural hematoma in the only patient with group 3 finding could be detected with 
all MRI sequences and CT images.
Discussion
Candidates to tcMRgFUS undergo pretreatment neuroimaging screening with CT and MRI which may lead to 
unexpected detection of incidental imaging findings. In this study we investigated the prevalence and significance 
of preoperative neuroradiological findings in a prospectively-enrolled cohort of candidates to tcMRgFUS. In 
our study, preoperative neuroimaging findings were present in 87.8% of patients, with a significantly positive 
correlation with patients’ age (p < 0.001). Most of the preoperative findings (81.5%) were classified as group 1, 
without significant implications for the treatments. Particularly, gliotic foci and signs of chronic hypoxic-ischemic 
encephalopathy were the most common imaging findings in our population (39.0% and 18.5%, respectively), and 
they typically did not require NPRs placement since they do not affect HI-FU transmission, even if potentially 
clinically  relevant34. Only one patient with a hemispheric subdural hematoma, incidentally discovered on neu-
roradiological screening examinations, was classified in the group 3 and therefore excluded from the procedure.
TcMRgFUS allows high energy deposition in a precise target (i.e. nucleus ventralis intermedius in patients 
with tremor) inducing coagulation necrosis without thermal injury to the non-target surrounding tissues. Prior 
evidences have reported a high success rate and safety of tcMRgFUS, with most of adverse events being mild and 
 transient21,35–38. Adverse events may be related to HI-FU passage (i.e. as headache, vertigo, nausea and vomiting) 
or to the ultrasound ablation thalamotomy and subsequent edema surrounding the ablated area (i.e. temporary 
paresthesia or ataxia)21,38. Several factors have been investigated and correlated with the rate of successful treat-
ments. The skull is the most critical barrier to the ultrasound delivery. Skull density ratio and skull volume are 
well-known factors affecting the thermal  rise32,39. Prior studies have also reported a correlation between the 
number of elements on and thermal rise during  sonications39. As a consequence, a total number of at least 700 
effective elements and a skull area of at least 250  cm2 are mandatory conditions for the  treatment2,31. Preoperative 
Figure 3.  70-year-old man with essential tremor. Preoperative SWAN sequence detects a hypointense lesion 
in the left frontal lobe (A, arrow), not corresponding to calcification on CT image (B). Axial and coronal 
intraoperative T2-weighted FRFSE show the no-pass region that was placed during treatment planning [red 
circles in (C) and (D)], blocking 4 additional elements (4.6% of the total elements turned off).
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neuroimaging findings may have a significant impact for patients eligibility to tcMRgFUS and may necessitate 
to reduce a large number of available FUS elements below the treatment cutoff.
Figure 4.  81-year-old woman with essential tremor. Preoperative axial (A) and sagittal (B) multiplanar 
reconstructions (3 mm thick, average algorithm) from post-contrast T1w 3D BRAVO demonstrate a 11 mm 
extra-axial lesion compatible with meningioma (arrows). A developmental venous anomaly in the left fronto-
parietal region is also present (white circle). Sagittal intraoperative T2-weighted FRFSE images show no-pass 
regions (red circles) with blocked [(C) red lines] and active [(D) green lines] elements. A total of 13 additional 
elements (11.6% of all blocked elements) were turned off due to the presence of the meningioma. 48-h follow-up 
axial T2-weighted FRFSE sequence (E) shows the FUS-placed lesion in the left nucleus ventralis intermedius. 
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In our experience, no complications related to the reported preoperative imaging findings were observed at 
intraoperative imaging or subsequent follow-ups. However, 26 (17.8%) neuroimaging findings in 23 (25.6%) 
patients were classified as group 2, with potential treatment implications. Among them, most of group 2 findings 
were SWAN hypointense lesions, not corresponding to calcifications on CT, accounting with a prevalence of 
16.7% in our population. SWAN hypointense lesions may represent areas of tissue inhomogeneity and interfaces 
which could potentially lead to cavitation phenomena and direct damage to  tissue40. In our experience we recom-
mend placement of NPRs in these lesions to impede the ultrasound delivery and mitigate the potential risk of 
potential unwanted heating. Overall, the presence of group 2 findings resulted in an additional mean reduction 
of 6.2% elements. However, these additional NPRs did not significantly decrease the number of active FUS ele-
ments compared to the patients without group 2 findings and none of them reduced the active FUS elements 
below the threshold of 700, which is the cutoff that allow the  treatment2,31. Further studies are needed to test 
the safety of tcMRgFUS in patients with specific neuroradiological findings and the risk of thermal/cavitation 
damage associated with these lesions.
Only few prior reports of tcMRgFUS treatment exist in patients with specific neuroradiological 
 conditions36,41,42 or with intraoperative  imaging43. Yang et al.41 reported a tcMRgFUS treatment in a patient with 
essential tremor and ventricular shunt for normal pressure hydrocephalus requiring 6% or ultrasound elements 
being shut off. Recently, Máñez-Miró et al.42 reported the first successful tcMRgFUS thalamotomy in a patient 
with multiple sclerosis-associated tremor. In our study, three patients had multiple sclerosis and one of them had 
enhancing plaque during preoperative imaging that required reassessment after medical therapy. These patients 
were classified as group 2 since they should be carefully selected considering the treatment benefits and poten-
tial risk of non-reversible ablation in a brain with impaired compensatory mechanism due to multiple sclerosis 
 plaques42. In our population two patients with meningioma (one of them entirely calcified) and one patient with 
a cavernoma (in the frontal lobe) were successfully treated with tcMRgFUS without complications, while two 
patients with a cavernoma of the left cingulate cortex and of the cerebellar hemisphere refused the treatment after 
being fully informed about procedure risks and benefits. To the best of our knowledge this is the first report dedi-
cated to the role of incidental imaging findings identification in patients underwent to tcMRgFUS thalamotomy.
Nowadays there is no consensus regarding the optimal preoperative screening protocol. Only few prior stud-
ies have detailed the sequences acquired in preoperative  imaging7,44–46. In our University Hospital, T2w FRFSE 
is a key sequence for treatment planning, but it may identify only a limited number of preoperative findings 
and furthermore these sequences are acquired with a coverage limited to the basal ganglia region. In our study, 
most of the group 2 findings were identified on SWAN sequences. This sequence is particularly helpful in the 
identification of small hypointense foci without correlate on CT, likely corresponding to hemosiderin deposits 
that require NPRs placement. Thus, including susceptibility-weighted sequences in MRI screening protocol is 
highly recommendable. Post-contrast imaging had an also an important role in the preoperative workup and 
allowed to identity lesions as small meningioma, active plaque in multiple sclerosis, acoustic schwannoma, and 
developmental venous anomalies.
Our study has a major limitation that needs to be acknowledge. In our population, only patients with a con-
firmed diagnosis and confirmed clinical indication at neurological and neurosurgical screening undergo CT 
and MRI screening examinations. Therefore, our findings may not be representative of all patients with essential 
tremor, Parkinson disease, neuropathic pain, or other neurodegenerative diseases. A further limitation of our 
study concerns the classification in the three groups of imaging findings on which this study is based. This clas-
sification if of course not comprehensive of all neuroradiological findings that could be found in a candidate to 
this cutting-edge non-invasive procedure but at the same time it includes the most common which may require 
specific technical measures. For example, the finding of large benign tumor lesions (i.e.: meningioma of the con-
vexity for near field exposure or of the skull base far-field exposure), severe metal deposits in the basal ganglia 
or other neuroradiological findings not evaluated in the current paper will require further studies and insights 
to clarify the safety and feasibility of these procedures in these borderline conditions.
In conclusion, preoperative neuroradiological findings are frequently encountered in candidates to tcMRgFUS 
and their identification may require the placement of additional no-pass regions. In our experience, the additional 
findings did not significantly affect the number of FUS elements. Nevertheless, marking SAWN hypointense 
lesions or other group 2 lesions as no pass regions should be considered mandatory to avoid unwanted heat-
ing and related possible damage to untargeted brain structures. Considering the growing trend of tcMRgFUS 
procedures for functional neurological disorders and the expanding number of experimental applications, we 
suggest that more and more attention should to be given to potentially harmful imaging findings to offer this 
therapeutic option to an ever-increasing number of patients.
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